Search results for " systemic lupus erythematosus"

showing 10 items of 11 documents

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

AORTIC STIFFNESS IS INCREASED IN NORMOTENSIVE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Abstracts from the 17th National Congress of the Italian Soc…

2019

Introduction: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular (CV) events. A marker of early vascular aging (EVA) is aortic pulse wave velocity (aPWV) which is a measure of arterial stiffness. Aim: To evaluate aPWV and the prevalence of EVA in a group of normotensive patients with SLE and to compare these values with those obtained in age- and gender-matched control subjects. Method: Aortic PWV was measured by a validated oscillometric device (Arteriograph). EVA was identified when the age-adjusted z-score of aPWV exceeded ? 1.96 (EVA1). The aPWV z-score was calculated using the ratio ‘‘Observed PWV–Predicted PWV/SD Predicted’’ and we obt…

AORTIC STIFFNESS - systemic lupus erythematosus - EARLY VASCULAR AGING
researchProduct

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

2020

Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of peo…

Drugmedicine.medical_specialtyPost exposureCoronavirus disease 2019 (COVID-19)COVID19media_common.quotation_subject030231 tropical medicineHydroxychloroquine ; COVID-19 ; Chloroquine ; SARS-CoV2 ; antiviral ; malaria ; Systemic lupus erythematosus ; Immunomodulation ; CoronavirusLoading doseImmunomodulation03 medical and health sciencesSystemic lupus erythematosus0302 clinical medicineChloroquineInternal medicineMedicine030212 general & internal medicineCoronavirus malaria antiviralmedia_commonlcsh:R5-920business.industryStandard treatmentPublic Health Environmental and Occupational HealthChloroquineHydroxychloroquineClinical trialEditorialInfectious DiseasesSARS-CoV2lcsh:Medicine (General)businessHydroxychloroquinemedicine.drugOne Health
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

Increased gingival blood vessel density in SLE patients

2012

Systemic lupus erythematosus (SLE) is a serious multisystem disease with a variety of cutaneous and oral manifestations. It is an autoimmune disorder whereby patients develop autoantibodies to many of their cells, cell components, and tissue. The microvascular changes in SLE play a role in the pathogenesis of this disease. The aim of this study was to investigate the gingival microcirculation in SLE patients. METHOD AND MATERIALs: Fifteen SLE patients and 15 healthy subjects were recruited for this study. Gingival microcirculation was investigated using videocapillaroscopy, a noninvasive technique that permits the in vivo evaluation of microvascular patterns. RESULTS: Significant difference…

Settore MED/28 - Malattie Odontostomatologichegingival vessels Systemic lupus erythematosus
researchProduct

DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling.

2022

Background: Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans. Objectives: To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human. Methods: We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile …

VasculitisEndodeoxyribonucleasesImmunologyDNAInflammatory Bowel DiseasesLupus NephritisChromatinANCA Apoptosis DNASE1L3 Interferon-stimulated genes Nucleic acids Systemic lupus erythematosus Type I interferonAntibodies Antineutrophil CytoplasmicSettore MED/38 - Pediatria Generale E SpecialisticaPhenotypeInterferon Type IImmunology and AllergyHumansLupus Erythematosus SystemicInterferonsJournal of clinical immunology
researchProduct

Pattern of cognitive impairment in systemic lupus erythematosus patients

2000

cognitive impairment systemic lupus erythematosusSettore MED/26 - Neurologia
researchProduct

Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis…

2022

Abstract Although each autoimmune disease is associated with specific tissue or organ damage, rheumatic diseases share a pro-inflammatory pattern that might increase cardiovascular risk. Retrospective and prospective studies on patients affected by systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) highlighted the concept of “accelerated atherosclerosis”. Therefore, the purpose of this systematic review and meta-analysis is the assessment of symptomatic or asymptomatic cardiovascular events among patients with rheumatic diseases as RA and SLE. The literature research obtained all manuscripts published in the English language between 2015 and 2019 for a total of 2355 manuscript…

medicine.medical_specialtyImmunologyDiseaseAsymptomaticArthritis RheumatoidRisk FactorsInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and AllergyProspective StudiesProspective cohort studyRetrospective StudiesAutoimmune diseasebusiness.industryIncidence (epidemiology)medicine.diseaseCardiovascular DiseasesHeart Disease Risk FactorsAge Cardiovascular events Metaanalysis Rheumatoid arthritis Risk Systemic lupus erythematosusMeta-analysisRheumatoid arthritisInclusion and exclusion criteriamedicine.symptombusinessAutoimmunity Reviews
researchProduct